DaVita Inc. (DVA)

NYSE: DVA · Real-Time Price · USD
148.44
-1.26 (-0.84%)
At close: Apr 8, 2026, 4:00 PM EDT
148.44
0.00 (0.00%)
After-hours: Apr 8, 2026, 7:00 PM EDT
Market Cap9.91B -16.4%
Revenue (ttm)13.64B +6.5%
Net Income746.80M -20.2%
EPS9.84 -8.3%
Shares Out 66.78M
PE Ratio15.74
Forward PE10.60
Dividendn/a
Ex-Dividend Daten/a
Volume737,388
Open151.31
Previous Close149.70
Day's Range148.29 - 153.00
52-Week Range101.00 - 159.42
Beta0.92
AnalystsHold
Price Target156.75 (+5.6%)
Earnings DateMay 11, 2026

About DVA

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In... [Read more]

Sector Healthcare
IPO Date Oct 31, 1995
Employees 78,000
Stock Exchange NYSE
Ticker Symbol DVA
Full Company Profile

Financial Performance

In 2025, DaVita's revenue was $13.64 billion, an increase of 6.46% compared to the previous year's $12.82 billion. Earnings were $746.80 million, a decrease of -20.24%.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for DVA stock is "Hold." The 12-month stock price target is $156.75, which is an increase of 5.60% from the latest price.

Price Target
$156.75
(5.60% upside)
Analyst Consensus: Hold
Stock Forecasts

News

DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement

Disclaimer: The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy an...

21 days ago - PRNewsWire

R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global dev...

22 days ago - GlobeNewsWire

DaVita Inc. to Participate in TD Cowen's 46th Annual Health Care Conference

DENVER, Feb. 24, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will par...

6 weeks ago - PRNewsWire

20 stocks of companies that delivered a double dose of growth this earnings season

Companies in the S&P 500 achieving double-digit sales growth while improving profit margins include Palantir, Micron, Boeing and Alphabet.

2 months ago - Market Watch

DaVita Stock Rallies On Profit Beat, Confident 2026 View

DaVita Inc. (NYSE: DVA) stock surged on Tuesday after the company reported upbeat fourth-quarter earnings and fiscal 2026 guidance.

2 months ago - Benzinga

TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings

The AI trade is helping Teradyne (TER), with Diane King Hall pointing to the company's latest earnings as a signal of forward strength. Outside of tech, she notes DaVita's (DVA) earnings beat and guid...

Other symbols: PEPTER
2 months ago - Schwab Network

DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump

DaVita projected annual profit above estimates on Monday after reporting better-than-expected fourth-quarter results on steady demand for its kidney dialysis services, sending its shares up 13% in aft...

2 months ago - Reuters

DaVita Inc. 4th Quarter 2025 Results

DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 20...

2 months ago - PRNewsWire

DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

DENVER, Jan. 21, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Monday, February 2, 2026 at 5:00 p.m...

2 months ago - PRNewsWire

DaVita Names New Leaders to Accelerate Care Transformation

Appointments of Chief People Officer and Chief Strategy Officer underscore commitment to innovation and people-first approach DENVER , Dec. 11, 2025 /PRNewswire/ -- DaVita, a leading provider of kidne...

4 months ago - PRNewsWire

DaVita Inc. to Participate in Fireside Chat with Wolfe Research

DENVER , Nov. 14, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Con...

5 months ago - PRNewsWire

DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025

Six  new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care DENVER and HOUSTON , Nov. 4, 2025 /PRNewsw...

5 months ago - PRNewsWire

DaVita misses quarterly profit estimates on rising costs, lower volumes

DaVita missed Wall Street estimates for third-quarter profit on Wednesday, as the kidney dialysis provider grappled with rising patient care costs and declining treatment volumes.

5 months ago - Reuters

DaVita Inc. 3rd Quarter 2025 Results

DENVER , Oct. 29, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025. "Our third quarter performance was in line with our e...

5 months ago - PRNewsWire

DaVita Leads the Way in Evaluating Middle Molecule Clearance with Two New Initiatives

New U.S. data will offer first-of-its-kind evidence in patients with kidney failure  DENVER , Oct. 20, 2025 /PRNewswire/ -- DaVita today announced the launch of two groundbreaking initiatives aimed to...

6 months ago - PRNewsWire

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

DENVER , Oct. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Wednesday, October 29, 2025, at 5:00...

6 months ago - PRNewsWire

DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care

Largest kidney care research arm advances science to inform care delivery DENVER , Aug. 27, 2025 /PRNewswire/ -- As part of its 25th-anniversary celebration, DaVita, a leading provider of comprehensiv...

8 months ago - PRNewsWire

Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows

A ransomware attack that encrypted certain elements of dialysis firm DaVita's network affected 2.7 million people, the U.S. health department's website showed on Thursday.

8 months ago - Reuters

DaVita beats quarterly profit on steady demand for dialysis services

DaVita beat Wall Street estimates for second-quarter profit on Tuesday, driven by demand for its kidney dialysis services.

8 months ago - Reuters

DaVita Inc. 2nd Quarter 2025 Results

DENVER , Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by our unwav...

8 months ago - PRNewsWire

DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

DENVER , July 17, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 5, 2025, at 5:00 p....

9 months ago - PRNewsWire

20 stocks primed for rapid growth while trading at half of Nvidia's valuation

When selecting investments, it is easy to get hung up on a particular metric, such as a dividend yield or a price ratio, but investors need to look deeper or they might miss opportunities.

11 months ago - Market Watch

DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

DENVER , May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation ...

11 months ago - PRNewsWire

DaVita Inc. Announces Upsize and Pricing of $1 Billion Senior Notes Offering

DENVER , May 20, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) ("DaVita") announced today the upsize and pricing of its previously announced private offering (the "offering") of its 6.750% senior notes...

11 months ago - PRNewsWire

DaVita Releases Annual Community Care Report, Highlights Achievements in Corporate Citizenship

Captures key initiatives achieved in 2024, driving 2025 ESG goals DENVER , May 20, 2025 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its Community Care report, underpinning its long-standing co...

11 months ago - PRNewsWire